GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults
Phase 2
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix™-BBiological: HBV-MPL vaccine 208129
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2008-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT00697853
- Locations
- 🇧🇪
GSK Clinical Trial Call Center, Brussels, Belgium
Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: HBsAg formulated with different concentrations of MPL and Aluminium SaltsBiological: Engerix™-B
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2008-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 321
- Registration Number
- NCT00697970
- Locations
- 🇦🇹
GSK Clinical Trials Call Center, Vienna, Austria
Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: HBV-MPL vaccine 208129Biological: Engerix™-B
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 951
- Registration Number
- NCT00697866
Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: MPL-Adjuvanted recombinant hepatitis B vaccineBiological: Engerix™-B
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2008-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00698087
- Locations
- 🇦🇹
GSK Clinical Trials Call Center, Vienna, Austria
Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix™-BBiological: HBV-MPL vaccine 208129
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 93
- Registration Number
- NCT00697554
Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants
Phase 2
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix™-BBiological: Hepatitis B vaccine, experimental formulationBiological: HBV-MPL vaccine (208129)
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2008-06-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00697125
- Locations
- 🇧🇪
GSK Clinical Trials Call Center, Gent, Belgium
Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPLBiological: Engerix™-B
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2008-06-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 362
- Registration Number
- NCT00697242
- Locations
- 🇮🇸
GSK Clinical Trials Call Center, Reykjavik, Iceland
Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix™-BBiological: HBV-MPL vaccine 208129
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2008-06-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1303
- Registration Number
- NCT00696917
- Locations
- 🇬🇧
GSK Clinical Trials Call Center, London, United Kingdom
Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: HBV-MPL vaccineBiological: Engerix™-B
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2008-06-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 380
- Registration Number
- NCT00696891
- Locations
- 🇸🇪
GSK Clinical Trials Call Center, Göteborg, Sweden
Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: HBV-MPL vaccine 208129Biological: Engerix™-B
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2008-06-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 340
- Registration Number
- NCT00697216
- Locations
- 🇩🇰
GSK Clinical Trials Call Center, Copenhagen, Denmark
© Copyright 2025. All Rights Reserved by MedPath